<code id='81A933CE61'></code><style id='81A933CE61'></style>
    • <acronym id='81A933CE61'></acronym>
      <center id='81A933CE61'><center id='81A933CE61'><tfoot id='81A933CE61'></tfoot></center><abbr id='81A933CE61'><dir id='81A933CE61'><tfoot id='81A933CE61'></tfoot><noframes id='81A933CE61'>

    • <optgroup id='81A933CE61'><strike id='81A933CE61'><sup id='81A933CE61'></sup></strike><code id='81A933CE61'></code></optgroup>
        1. <b id='81A933CE61'><label id='81A933CE61'><select id='81A933CE61'><dt id='81A933CE61'><span id='81A933CE61'></span></dt></select></label></b><u id='81A933CE61'></u>
          <i id='81A933CE61'><strike id='81A933CE61'><tt id='81A933CE61'><pre id='81A933CE61'></pre></tt></strike></i>

          Home / comprehensive / Wikipedia

          Wikipedia


          Wikipedia

          author:Wikipedia    Page View:7
          Roche HQ
          SEBASTIEN BOZON/AFP via Getty Images

          The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

          Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

          advertisement

          The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In